Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

The Genetic Architecture of Gliomagenesis-Genetic Risk Variants Linked to Specific Molecular Subtypes.

Wu WY, Johansson G, Wibom C, Brännström T, Malmström A, Henriksson R, Golovleva I, Bondy ML, Andersson U, Dahlin AM, Melin B.

Cancers (Basel). 2019 Dec 12;11(12). pii: E2001. doi: 10.3390/cancers11122001. Review.

2.

Genetic Variants in the 9p21.3 Locus Associated with Glioma Risk in Children, Adolescents, and Young Adults: A Case-Control Study.

Dahlin AM, Wibom C, Andersson U, Hougaard DM, Bybjerg-Grauholm J, Deltour I, Hultman CM, Kähler AK, Karlsson R, Hjalmars U, Melin B.

Cancer Epidemiol Biomarkers Prev. 2019 Jul;28(7):1252-1258. doi: 10.1158/1055-9965.EPI-18-1026. Epub 2019 Apr 30.

PMID:
31040135
3.

Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples.

Späth F, Wibom C, Krop EJM, Santamaria AI, Johansson AS, Bergdahl IA, Hultdin J, Vermeulen R, Melin B.

Haematologica. 2019 Dec;104(12):2456-2464. doi: 10.3324/haematol.2019.216895. Epub 2019 Apr 4.

4.

A geographically matched control population efficiently limits the number of candidate disease-causing variants in an unbiased whole-genome analysis.

Rentoft M, Svensson D, Sjödin A, Olason PI, Sjöström O, Nylander C, Osterman P, Sjögren R, Netotea S, Wibom C, Cederquist K, Chabes A, Trygg J, Melin BS, Johansson E.

PLoS One. 2019 Mar 27;14(3):e0213350. doi: 10.1371/journal.pone.0213350. eCollection 2019.

5.

The association between longer relative leukocyte telomere length and risk of glioma is independent of the potentially confounding factors allergy, BMI, and smoking.

Andersson U, Degerman S, Dahlin AM, Wibom C, Johansson G, Bondy ML, Melin BS.

Cancer Causes Control. 2019 Feb;30(2):177-185. doi: 10.1007/s10552-018-1120-2. Epub 2018 Dec 17.

PMID:
30560391
6.

Biomarker Dynamics in B-cell Lymphoma: A Longitudinal Prospective Study of Plasma Samples Up to 25 Years before Diagnosis.

Späth F, Wibom C, Krop EJ, Johansson AS, Bergdahl IA, Vermeulen R, Melin B.

Cancer Res. 2017 Mar 15;77(6):1408-1415. doi: 10.1158/0008-5472.CAN-16-2345. Epub 2017 Jan 20.

7.

Relation between Established Glioma Risk Variants and DNA Methylation in the Tumor.

Dahlin AM, Wibom C, Ghasimi S, Brännström T, Andersson U, Melin B.

PLoS One. 2016 Oct 25;11(10):e0163067. doi: 10.1371/journal.pone.0163067. eCollection 2016.

8.

Metabolomic screening of pre-diagnostic serum samples identifies association between α- and γ-tocopherols and glioblastoma risk.

Björkblom B, Wibom C, Jonsson P, Mörén L, Andersson U, Johannesen TB, Langseth H, Antti H, Melin B.

Oncotarget. 2016 Jun 14;7(24):37043-37053. doi: 10.18632/oncotarget.9242.

9.

Characterization of the serum metabolome following radiation treatment in patients with high-grade gliomas.

Mörén L, Wibom C, Bergström P, Johansson M, Antti H, Bergenheim AT.

Radiat Oncol. 2016 Apr 2;11:51. doi: 10.1186/s13014-016-0626-6.

10.

Pre-diagnostic serum levels of EGFR and ErbB2 and genetic glioma risk variants: a nested case-control study.

Späth F, Andersson U, Dahlin AM, Langseth H, Hovig E, Johannesen TB, Grankvist K, Björkblom B, Wibom C, Melin B.

Tumour Biol. 2016 Aug;37(8):11065-72. doi: 10.1007/s13277-015-4742-y. Epub 2016 Feb 23.

11.

Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma.

Ghasimi S, Wibom C, Dahlin AM, Brännström T, Golovleva I, Andersson U, Melin B.

J Neurooncol. 2016 May;127(3):483-92. doi: 10.1007/s11060-016-2066-4. Epub 2016 Feb 2.

12.

Whole-genome sequencing identifies EN1 as a determinant of bone density and fracture.

Zheng HF, Forgetta V, Hsu YH, Estrada K, Rosello-Diez A, Leo PJ, Dahia CL, Park-Min KH, Tobias JH, Kooperberg C, Kleinman A, Styrkarsdottir U, Liu CT, Uggla C, Evans DS, Nielson CM, Walter K, Pettersson-Kymmer U, McCarthy S, Eriksson J, Kwan T, Jhamai M, Trajanoska K, Memari Y, Min J, Huang J, Danecek P, Wilmot B, Li R, Chou WC, Mokry LE, Moayyeri A, Claussnitzer M, Cheng CH, Cheung W, Medina-Gómez C, Ge B, Chen SH, Choi K, Oei L, Fraser J, Kraaij R, Hibbs MA, Gregson CL, Paquette D, Hofman A, Wibom C, Tranah GJ, Marshall M, Gardiner BB, Cremin K, Auer P, Hsu L, Ring S, Tung JY, Thorleifsson G, Enneman AW, van Schoor NM, de Groot LC, van der Velde N, Melin B, Kemp JP, Christiansen C, Sayers A, Zhou Y, Calderari S, van Rooij J, Carlson C, Peters U, Berlivet S, Dostie J, Uitterlinden AG, Williams SR, Farber C, Grinberg D, LaCroix AZ, Haessler J, Chasman DI, Giulianini F, Rose LM, Ridker PM, Eisman JA, Nguyen TV, Center JR, Nogues X, Garcia-Giralt N, Launer LL, Gudnason V, Mellström D, Vandenput L, Amin N, van Duijn CM, Karlsson MK, Ljunggren Ö, Svensson O, Hallmans G, Rousseau F, Giroux S, Bussière J, Arp PP, Koromani F, Prince RL, Lewis JR, Langdahl BL, Hermann AP, Jensen JE, Kaptoge S, Khaw KT, Reeve J, Formosa MM, Xuereb-Anastasi A, Åkesson K, McGuigan FE, Garg G, Olmos JM, Zarrabeitia MT, Riancho JA, Ralston SH, Alonso N, Jiang X, Goltzman D, Pastinen T, Grundberg E, Gauguier D, Orwoll ES, Karasik D, Davey-Smith G; AOGC Consortium, Smith AV, Siggeirsdottir K, Harris TB, Zillikens MC, van Meurs JB, Thorsteinsdottir U, Maurano MT, Timpson NJ, Soranzo N, Durbin R, Wilson SG, Ntzani EE, Brown MA, Stefansson K, Hinds DA, Spector T, Cupples LA, Ohlsson C, Greenwood CM; UK10K Consortium, Jackson RD, Rowe DW, Loomis CA, Evans DM, Ackert-Bicknell CL, Joyner AL, Duncan EL, Kiel DP, Rivadeneira F, Richards JB.

Nature. 2015 Oct 1;526(7571):112-7. doi: 10.1038/nature14878. Epub 2015 Sep 14.

13.

CCND2, CTNNB1, DDX3X, GLI2, SMARCA4, MYC, MYCN, PTCH1, TP53, and MLL2 gene variants and risk of childhood medulloblastoma.

Dahlin AM, Hollegaard MV, Wibom C, Andersson U, Hougaard DM, Deltour I, Hjalmars U, Melin B.

J Neurooncol. 2015 Oct;125(1):75-8. doi: 10.1007/s11060-015-1891-1. Epub 2015 Aug 20.

14.

Investigation of established genetic risk variants for glioma in prediagnostic samples from a population-based nested case-control study.

Wibom C, Späth F, Dahlin AM, Langseth H, Hovig E, Rajaraman P, Johannesen TB, Andersson U, Melin B.

Cancer Epidemiol Biomarkers Prev. 2015 May;24(5):810-6. doi: 10.1158/1055-9965.EPI-14-1106. Epub 2015 Feb 20.

15.

Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer.

Andersson U, Wibom C, Cederquist K, Aradottir S, Borg A, Armstrong GN, Shete S, Lau CC, Bainbridge MN, Claus EB, Barnholtz-Sloan J, Lai R, Il'yasova D, Houlston RS, Schildkraut J, Bernstein JL, Olson SH, Jenkins RB, Lachance DH, Wrensch M, Davis FG, Merrell R, Johansen C, Sadetzki S; Gliogene Consortium, Bondy ML, Melin BS.

Neuro Oncol. 2014 Oct;16(10):1333-40. doi: 10.1093/neuonc/nou052. Epub 2014 Apr 9.

16.

Protein expression profiling of brain tumor tissue using SELDI-MS.

Wibom C.

Methods Mol Biol. 2013;1023:191-202. doi: 10.1007/978-1-4614-7209-4_13.

PMID:
23765628
17.

EGFR gene variants are associated with specific somatic aberrations in glioma.

Wibom C, Ghasimi S, Van Loo P, Brännström T, Trygg J, Lau C, Henriksson R, Bergenheim T, Andersson U, Rydén P, Melin B.

PLoS One. 2012;7(12):e47929. doi: 10.1371/journal.pone.0047929. Epub 2012 Dec 7.

18.

Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors.

Asklund T, Kvarnbrink S, Holmlund C, Wibom C, Bergenheim T, Henriksson R, Hedman H.

Anticancer Res. 2012 Jul;32(7):2407-13.

PMID:
22753697
19.

DNA-repair gene variants are associated with glioblastoma survival.

Wibom C, Sjöström S, Henriksson R, Brännström T, Broholm H, Rydén P, Johansen C, Collatz-Laier H, Hepworth S, McKinney PA, Bethke L, Houlston RS, Andersson U, Melin BS.

Acta Oncol. 2012 Mar;51(3):325-32. doi: 10.3109/0284186X.2011.616284. Epub 2011 Oct 21.

PMID:
22017238
20.

Analysis of DNA repair gene polymorphisms and survival in low-grade and anaplastic gliomas.

Berntsson SG, Wibom C, Sjöström S, Henriksson R, Brännström T, Broholm H, Johansson C, Fleming SJ, McKinney PA, Bethke L, Houlston R, Smits A, Andersson U, Melin BS.

J Neurooncol. 2011 Dec;105(3):531-8. doi: 10.1007/s11060-011-0614-5. Epub 2011 Jun 5.

PMID:
21643987
21.

Genetic variations in VEGF and VEGFR2 and glioblastoma outcome.

Sjöström S, Wibom C, Andersson U, Brännström T, Broholm H, Johansen C, Collatz-Laier H, Liu Y, Bondy M, Henriksson R, Melin B.

J Neurooncol. 2011 Sep;104(2):523-7. doi: 10.1007/s11060-010-0504-2. Epub 2010 Dec 30.

22.

Vandetanib alters the protein pattern in malignant glioma and normal brain in the BT4C rat glioma model.

Wibom C, Sandström M, Henriksson R, Antti H, Johansson M, Bergenheim AT.

Int J Oncol. 2010 Oct;37(4):879-90.

PMID:
20811710
23.

Metabolomic patterns in glioblastoma and changes during radiotherapy: a clinical microdialysis study.

Wibom C, Surowiec I, Mörén L, Bergström P, Johansson M, Antti H, Bergenheim AT.

J Proteome Res. 2010 Jun 4;9(6):2909-19. doi: 10.1021/pr901088r.

PMID:
20302353
24.

Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype.

Wibom C, Mörén L, Aarhus M, Knappskog PM, Lund-Johansen M, Antti H, Bergenheim AT.

J Neurooncol. 2009 Sep;94(3):321-31. doi: 10.1007/s11060-009-9865-9. Epub 2009 Apr 7.

PMID:
19350207
25.

Cutaneous and mucosal human papillomaviruses differ in net surface charge, potential impact on tropism.

Mistry N, Wibom C, Evander M.

Virol J. 2008 Oct 14;5:118. doi: 10.1186/1743-422X-5-118.

26.

Protein expression in experimental malignant glioma varies over time and is altered by radiotherapy treatment.

Wibom C, Pettersson F, Sjöström M, Henriksson R, Johansson M, Bergenheim AT.

Br J Cancer. 2006 Jun 19;94(12):1853-63. Epub 2006 May 30. Erratum in: Br J Cancer. 2006 Sep 18;95(6):766.

27.

Successful ovulation in plasminogen-deficient mice treated with the broad-spectrum matrix metalloproteinase inhibitor galardin.

Liu K, Wahlberg P, Leonardsson G, Hägglund AC, Ny A, Bodén I, Wibom C, Lund LR, Ny T.

Dev Biol. 2006 Jul 15;295(2):615-22. Epub 2006 Apr 7.

Supplemental Content

Support Center